Biogen, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
    • Gene Therapy, Cell Therapy
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • Biogen Dompé
  • Biogen Idec
  • Conforma Therapeutics
  • Convergence Pharmaceuticals
  • Fumapharm
  • Human Immunology Biosciences (HI-Bio)
  • Nightstar Therapeutics
  • Reata Pharmaceuticals
  • Syntonix Pharmaceuticals
  • Stromedix
See more in Biomedtracker

Latest on Biogen, Inc.

Scrip

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D

Pink Sheet

What Information Does US FDA Need For Stealth’s Elamipretide After CRL?

 
• By Sue Sutter

A US Food and Drug Administration complete response letter that proposed accelerated approval as a potential path forward for Stealth Biotherapeutics ’ elamipretide raises questions about what additi

Scrip

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

Royalty Pharma has built a unique and valuable business model within the biopharma sector, buying royalty revenue streams in exchange for capital to finance drug development and commercialization. And

Scrip

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

Merck KGaA is pursuing a Phase III program for its novel toll-like receptor 7/8 inhibitor enpatoran in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), despite